Abstract Book - PDF - San Antonio Breast Cancer Symposium

CTRC-AACR San Antonio Breast Cancer Symposium
Detection/Diagnosis: Circulating Markers
P2-02-01 Accurate identification of metastatic breast cancer using
methylated gene markers in circulating free DNA in
peripheral blood
Sukumar S, Fackler MJ, Lopez-Bujanda Z, Teo WW, Jeter S, Umbricht
C, Visvanathan K, Wolff AC. Johns Hopkins University School of
Medicine, Baltimore, MD.
P2-02-02 Prognostic significance of the ratio of absolute neutrophil
to lymphocyte counts for breast cancer patients in
neoadjuvant setting
Koh YW, Lee HJ, Ahn J-H, Lee JW, Gong G. University of Ulsan
College of Medicine, Asan Medical Center, Seoul, Korea; Seoul
National University Bundang Hospital, Seongnam, Bundang-Gu,
Kyeonggi-Do, Korea.
P2-02-03 The Collagen Receptor Endo180: A Metastatic Plasma Marker
in Breast Cancer Modulated by Bisphosphonate Treatment
Sturge J, Caley MP, Purshouse K, Fonseca A-V, Rodriguez-Teja M,
Kogianni G, Waxman J, Palmieri C. Imperial College London, United
Kingdom; The University of Hull, Hull, United Kingdom.
P2-02-04 The interaction between menopausal status and
zoledronic acid can differentially affect serum levels of the
TGFβ superfamily
Wilson C, Winter MC, Holen I, Freeman JV, Evans AC, Coleman RE.
University of Sheffield, United Kingdom; Sheffield Teaching Hospitals
NHS Trust, Sheffield, United Kingdom.
Detection/Diagnosis: Micrometastases
P2-03-01 Identification of cancer stem cells (CD44+CD24-/lo) in bone
marrow as a prognostic factor in early breast cancer patients
Giordano A, Gao H, Cohen EN, Anfossi S, Hess KR, Krishnamurthy S,
Tin S, Cristofanilli M, Hortobagyi GN, Woodward WA, Ueno NT, Lucci
A, Reuben JM. The University of Texas MD Anderson Cancer Center,
Houston, TX; The University of Texas MD Anderson Cancer Center;
Fox Chase Cancer Center.
Tumor Cell and Molecular Biology: Animal Models
P2-04-01 Development of mouse breast cancer models based on
induced cancer stem cells (iCSC)
Takamoto Y, Onishi N, Kai K, Saya H. Institute for Advanced Medical
Research (IAMR), School of Medicine, Keio university, Shinjyuku-ku,
Tokyo, Japan; The University of Texas MD Anderson Cancer Center,
Houston, TX.
P2-04-02 Identification of genes associated with breast cancer
micrometastatic disease in bone marrow using a
human-in-mouse xenograft system
Aft R, Li S, Mudalagiriyappa C, Dasgupta N, Watson M, Fleming T, Ellis
M, Pillai S. Washington University, St. Louis, MO.
P2-04-03 A robust transgenic mouse model to study male breast cancer
Krause S, Lurvey HL, Tobin H, Ingber DE. Boston’s Children’s Hospital,
Boston, MA; Wyss Institute of Biologically Inspired Engineering,
Boston, MA.
P2-04-04 Prolactin cooperates with loss of p53 to promote
mammary tumorigenesis
O’Leary KA, Sullivan R, Rugowski DE, Schuler LA. University of
Wisconsin, Madison, WI.
P2-04-05 Prolonged targeted overexpression of Aurora-A in mammary
epithelium promotes mammary adenocarcinoma with
genomic instability
Treekitkarnmongkol W, Katayama H, Sen S. University of Texas M.D.
Anderson Cancer Center, Houston, TX.
P2-04-06 Transgenic expression of a breast-cancer specific GATA3
mutant leads to mammary hyperplasia
Kenny PA, Chandiramani N. Albert Einstein College of Medicine,
Bronx, NY.
P2-04-07 Modeling orthotopic and metastatic progression of
mammary tumors to evaluate the efficacy of TGF-β inhibitors
in a pre-clinical setting
Biswas T, Yang J, Zhao L, Sun L. UTHSCSA, San Antonio, TX;
UCSD, CA.
P2-04-08 Targeted Expression of the Human Chaperone BAG3 to the
Murine Mammary Gland Dysregulates Mammary Gland
Development and Differentiation By Unrestricted Expansion of
Luminal Cells
Virador VM, Casagrange G, Raafat A, Callahan R, Kohn E. National
Cancer Institute, Bethesda, MD.
Tumor Cell and Molecular Biology: Biomarkers
P2-05-01 Gene expression changes associated with response to
neoadjuvant chemotherapy are observed early in treatment:
results from the I-SPY 1 TRIAL (CALGB 150007/150012;
ACRIN 6657)
Wolf DM, Yau C, Magbanua M, Boudreau A, Davis S, Haqq C, Park J,
I-SPY TRIAL-1 Investigators, Esserman L, van’t Veer L. University of
California, San Francisco, CA; I-SPY 1 TRIAL Institutions.
P2-05-02 Clinical significance of microRNA regulator Lin28 expression in
patient with early breast cancer
Park S, Shin YK, Song BJ, Chae BJ, Jung SS, Choi Y-L. Seoul St. Mary’s
Hospital, Catholic University School of Medicine, Seoul, Korea; Seoul
National University College of Pharmacy, Seoul, Korea; Samsung
Medical Center, Sungkyunkwan University School of Medicine,
Seoul, Korea.
P2-05-03 Mouse double minute 2 nuclear expression as a prognostic
marker in patients with breast cancer
Park HS, Park S, Koo JS, Cho JH, Park JM, Kim S-I, Park B-W. Yonsei
University College of Medicine, Seodaemoon-gu, Seoul, Korea.
P2-05-04 Differential potency of TORC1/C2 (INK/MLN-128) and pan-PI3K
(GDC0941) inhibitors on breast cancer polysome composition
and phosphoprotein response biomarkers
Wilson-Edell KA, Yevtushenko M, Hanson I, Rogers AN, Scott GK,
Benz CC. Buck Institute for Research on Aging, Novato, CA.
P2-05-05 Circulating HER2 extracellular domain (ECD) predicts a poor
prognosis for metastatic breast cancer patients
Wang X-j, Shao X-Y, Xu X-H, Chen Z-H, Wang S, Cai J-F, Huang J,
Huang P, Lou C-J, Ling Z-Q, Han MX. Zhejiang Cancer Hospital,
Hangzhou, Zhejiang, China; Hangzhou Polar Gene Company,
Hangzhou, Zhejiang, China.
P2-05-06 Quantitative measurement of HER2 expression in breast
cancers: comparison with “real world” HER2 testing in a
multi-center Collaborative Biomarker Study (CBS) and
correlation with clinicopathological features
Yardley DA, Kaufman PA, Adams JW, Krekow L, Savin M, Lawler WE,
Zrada S, Starr A, Einhorn H, Schwartzberg LS, Huang W, Weidler J, Lie
Y, Paquet A, Haddad M, Anderson S, Brigino M, Bosserman L. Sarah
Cannon Research Institute, Nashville, TN; Tennessee Oncology PLLC,
Nashville, TN; Dartmouth Hitchcock Medical Center, Lebanon, NH;
Arlington Cancer Center, Arlington, TX; Texas Oncology Bedford,
Bedford, TX; Texas Oncology at Medical City Dallas 2, Dallas, TX; St.
Jude Heritage Medical Group, Fullerton, CA; The Center for Cancer
and Hematologic Disease, Cherry Hill, NJ; Monroe Medical Associates,
Harvey, IL; Swedish American Regional Cancer Center, Rockford,
IL; The West Clinic, Memphis, TN; Monogram Biosciences, Inc., So.
San Francisco, CA; Center for Molecular Biology and Pathology,
Laboratory Corporation of America, Inc., Research Triangle Park, NC;
Wilshire Oncology Medical Group, Rancho Cucamonga, CA.
P2-05-07 Comparison of hormone receptor and HER-2 expression in
primary breast cancers and sentinel lymph node metastases
Rokutanda N, Horiguchi J, Takata D, Nagaoka R, Sato A, Tokiniwa H,
Tozuka K, Uchida S, Takeyoshi I. Gunma University Graduate School
of Medicine, Maebashi, Gunma, Japan.
Cancer Res; 72(24 Suppl.) December 15, 2012 22s Cancer Research